Literature DB >> 33024274

Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis.

Fang Chen1, Qi Gao1, Ai Wei1, Xingren Chen1, Yujun Shi2, Hongwei Wang3,4, Wangsen Cao5.   

Abstract

Development of renal fibrosis is a hallmark of renal aging and chronic kidney disease of all etiologies and characterized by extensive renal cell injuries and subsequent myofibroblast transdifferentiations (MTDs), which are significantly influenced by aberrant histone deacetylase (HDAC) activities. However, the key HDAC isoforms and effectors that are causally involved in the processes remain poorly understood. Here, we report that aberrant HDAC3 induction and its inhibition of Klotho, a renal epithelium-enriched aging suppressor, contribute significantly to renal fibrogenesis. HDAC3 was preferentially elevated with concomitant Klotho suppression in fibrotic kidneys incurred by unilateral ureter obstruction (UUO) and aristolochic acid nephropathy (AAN), whereas Hdac3 knockout resisted the fibrotic pathologies. The HDAC3 elevation is substantially blocked by the inhibitors of TGFβ receptor and Smad3 phosphorylation, suggesting that TGFβ/Smad signal activates Hdac3 transcription. Consistently, an HDAC3-selective inhibitor RGFP966 derepressed Klotho and mitigated the renal fibrotic injuries in both UUO and AAN mice. Further, HDAC3 overexpression or inhibition in renal epithelia inversely affected Klotho abundances and HDAC3 was inducibly associated with transcription regulators NCoR and NF-kB and bound to Klotho promoter in fibrotic kidney, supporting that aberrant HDAC3 targets and transcriptionally inhibits Klotho under renal fibrotic conditions. More importantly, the antirenal fibrosis effects of RGFP966 were largely compromised in mice with siRNA-mediated Klotho knockdown. Hence, HDAC3 aberration and the subsequent Klotho suppression constitute an important regulatory loop that promotes MTD and renal fibrosis and uses of HDAC3-selective inhibitors are potentially effective in treating renal fibrotic disorders.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33024274      PMCID: PMC7937860          DOI: 10.1038/s41418-020-00631-9

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  51 in total

Review 1.  Mechanisms of tubulointerstitial fibrosis.

Authors:  Michael Zeisberg; Eric G Neilson
Journal:  J Am Soc Nephrol       Date:  2010-09-23       Impact factor: 10.121

2.  Inhibition of class I HDACs attenuates renal interstitial fibrosis in a murine model.

Authors:  Min Yang; Gen Chen; Xue Zhang; Yuliang Guo; Yan Yu; Li Tian; Sheng Chang; Zhonghua Klaus Chen
Journal:  Pharmacol Res       Date:  2019-02-23       Impact factor: 7.658

Review 3.  Epigenetics of progression of chronic kidney disease: fact or fantasy?

Authors:  Maria R Wing; Ali Ramezani; Harindarpal S Gill; Joseph M Devaney; Dominic S Raj
Journal:  Semin Nephrol       Date:  2013-07       Impact factor: 5.299

Review 4.  Renal fibrosis: novel insights into mechanisms and therapeutic targets.

Authors:  Peter Boor; Tammo Ostendorf; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2010-09-14       Impact factor: 28.314

5.  Class-specific histone/protein deacetylase inhibition protects against renal ischemia reperfusion injury and fibrosis formation.

Authors:  M H Levine; Z Wang; T R Bhatti; Y Wang; D D Aufhauser; S McNeal; Y Liu; S Cheraghlou; R Han; L Wang; W W Hancock
Journal:  Am J Transplant       Date:  2015-02-23       Impact factor: 8.086

6.  Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.

Authors:  Chongxiang Xiong; Yingjie Guan; Xiaoxu Zhou; Lirong Liu; Michelle A Zhuang; Wei Zhang; Yunhe Zhang; Monica V Masucci; George Bayliss; Ting C Zhao; Shougang Zhuang
Journal:  FASEB J       Date:  2019-04-05       Impact factor: 5.191

Review 7.  HDAC inhibitors in kidney development and disease.

Authors:  Lauren L Brilli; Lisa M Swanhart; Mark P de Caestecker; Neil A Hukriede
Journal:  Pediatr Nephrol       Date:  2012-10-07       Impact factor: 3.714

8.  Histone deacetylase inhibitor, CG200745 attenuates renal fibrosis in obstructive kidney disease.

Authors:  Hong Sang Choi; Ji Hong Song; In Jin Kim; Soo Yeon Joo; Gwang Hyeon Eom; Inkyeom Kim; Hyunju Cha; Joong Myung Cho; Seong Kwon Ma; Soo Wan Kim; Eun Hui Bae
Journal:  Sci Rep       Date:  2018-08-01       Impact factor: 4.379

Review 9.  Renal Inflammation and Fibrosis: A Double-edged Sword.

Authors:  Laurence M Black; Jeremie M Lever; Anupam Agarwal
Journal:  J Histochem Cytochem       Date:  2019-05-22       Impact factor: 2.479

10.  Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling.

Authors:  Na Liu; Song He; Li Ma; Murugavel Ponnusamy; Jinhua Tang; Evelyn Tolbert; George Bayliss; Ting C Zhao; Haidong Yan; Shougang Zhuang
Journal:  PLoS One       Date:  2013-01-16       Impact factor: 3.240

View more
  8 in total

Review 1.  Recent Advances in Epigenetics of Age-Related Kidney Diseases.

Authors:  Feng Liu; Jiefang Chen; Zhenqiong Li; Xianfang Meng
Journal:  Genes (Basel)       Date:  2022-04-29       Impact factor: 4.141

2.  Bovine serum albumin aggravates macrophage M1 activation and kidney injury in heterozygous Klotho-deficient mice via the gut microbiota-immune axis.

Authors:  Lingyun Lai; Yi Li; Jianjun Liu; Lei Luo; Jianguo Tang; Jun Xue; Te Liu
Journal:  Int J Biol Sci       Date:  2021-02-02       Impact factor: 6.580

Review 3.  Therapies Targeting Epigenetic Alterations in Acute Kidney Injury-to-Chronic Kidney Disease Transition.

Authors:  Fumiaki Tanemoto; Imari Mimura
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-20

4.  CCL5 Suppresses Klotho Expression via p-STAT3/DNA Methyltransferase1-Mediated Promoter Hypermethylation.

Authors:  QiFeng Liu; ShaSha Li; LiXia Yu; XiaoYa Yin; Xi Liu; JianMing Ye; GuoYuan Lu
Journal:  Front Physiol       Date:  2022-03-01       Impact factor: 4.566

Review 5.  Histone Acetylation and Modifiers in Renal Fibrosis.

Authors:  Fengchen Shen; Shougang Zhuang
Journal:  Front Pharmacol       Date:  2022-04-26       Impact factor: 5.988

Review 6.  Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression.

Authors:  Jiayu Wang; Jiaxing Li; Xin Zhang; Min Zhang; Xiaopeng Hu; Hang Yin
Journal:  Front Mol Biosci       Date:  2022-09-06

7.  HDAC5-mediated Smad7 silencing through MEF2A is critical for fibroblast activation and hypertrophic scar formation.

Authors:  Ya Gao; Yangdan Liu; Danning Zheng; Chiakang Ho; Dongsheng Wen; Jiaming Sun; Lu Huang; Yuxin Liu; Qingfeng Li; Yifan Zhang
Journal:  Int J Biol Sci       Date:  2022-09-11       Impact factor: 10.750

Review 8.  The critical roles of histone deacetylase 3 in the pathogenesis of solid organ injury.

Authors:  Li Ning; Xiong Rui; Wang Bo; Geng Qing
Journal:  Cell Death Dis       Date:  2021-07-23       Impact factor: 8.469

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.